ANI Pharma rises on expanded US approval for eye-disease drug

Shares of drugmaker ANI Pharmaceuticals ANIP.O rise 2% to $62.70

Co says the U.S. FDA has given expanded approval for Iluvien to treat chronic, non-infectious uveitis affecting the posterior segment of the eye (NIU-PS)

NIU-PS is characterized by inflammation of the retina or optic nerve of the eye

Iluvien is already approved by the FDA to treat another eye condition called diabetic macular edema (DME)

Co plans to market Iluvien under the combined label in the U.S. later this year

Up to last close, ANIP has fallen 7.2% in the past 12 months